Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancerJ.-Y. Douillard, R. Sidhu, Salvatore Siena et al.|Annals of Oncology|2014Cited by 603
Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancerMarc Peeters, R. Sidhu, Timothy Price et al.|Annals of Oncology|2013Cited by 220
Faecal lactoferrin – a novel test to differentiate between the irritable and inflamed bowel?R. Sidhu, David S. Sanders, Peter W.F. Wilson et al.|Alimentary Pharmacology & Therapeutics|2010Cited by 57
Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)Ryan B. Corcoran, Eric Van Cutsem, Autumn J. McRee et al.|Annals of Oncology|2016Cited by 46
Low rates of serious complications but high rates of hardware removal after high tibial osteotomy with Tomofix locking plateR. Sidhu, Alan Getgood, Gilbert Moatshe et al.|Knee Surgery Sports Traumatology Arthroscopy|2020Cited by 42